JCR Pharmaceuticals Management

Management criteria checks 2/4

JCR Pharmaceuticals' CEO is Shin Ashida, appointed in Jun 2005, has a tenure of 18.83 years. directly owns 0.008% of the company’s shares, worth ¥8.29M. The average tenure of the management team and the board of directors is 6.8 years and 4.3 years respectively.

Key information

Shin Ashida

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	18.8yrs
CEO ownership	0.008%
Management average tenure	6.8yrs
Board average tenure	4.3yrs

Recent management updates

Recent updates

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Mar 18

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Feb 29

CEO

Shin Ashida (80 yo)

18.8yrs

Tenure

Mr. Shin Ashida has been the Chairman of JCR Pharmaceuticals Co., Ltd. since July 1995 and its Chief Executive Officer since June 2005. Mr. Ashida has been the President of JCR Pharmaceuticals Co., Ltd., s...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Shin Ashida	Chairman	18.8yrs	no data	0.0083% ¥ 8.3m
Yoshihiro Ota	Director of Accounting Department & Corporate Strategy Department (Finance)	no data	no data	no data
Yutaka Honda	Senior Corporate Officer	7.8yrs	no data	no data
Hiroyuki Fukuya	Director of Legal Affairs Department - Administration Division	no data	no data	no data
Toru Ashida	Senior VP of Sales & Administration	4yrs	no data	0.21% ¥ 208.7m
Ryutaro Makino	Director of Marketing Dept. & Group Manager of Product Planning - Marketing Dept. for Sales Div.	3.5yrs	no data	no data
Katsuya Nishino	Executive Vice President	13.8yrs	no data	no data
Hiroshi Yoshimoto	Senior Advisor	12.9yrs	no data	no data
Takayo Egawa	Corporate Officer & Director of International Affairs Office	no data	no data	no data
Hiroyuki Sonoda	VP of Research & Corporate Strategy	5.8yrs	no data	0.0015% ¥ 1.5m
Kazunori Tanizawa	Corporate Officer & Executive Director of Development Division	no data	no data	no data
Mathias Schmidt	VP of Clinical Development	3.8yrs	no data	no data

6.8yrs

Average Tenure

61yo

Average Age

Experienced Management: 4552's management team is seasoned and experienced (6.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Shin Ashida	Chairman	18.8yrs	no data	0.0083% ¥ 8.3m
Toru Ashida	Senior VP of Sales & Administration	no data	no data	0.21% ¥ 208.7m
Hiroyuki Sonoda	VP of Research & Corporate Strategy	4.3yrs	no data	0.0015% ¥ 1.5m
Mathias Schmidt	VP of Clinical Development	4.3yrs	no data	no data
Yoshio Hiyama	Sr. Exec. Director	2.8yrs	no data	0.0013% ¥ 1.3m
Marc Dunoyer	Independent Outside Director	1.3yrs	no data	no data
Philippe Fauchet	Independent Outside Director	no data	no data	no data
Toshihide Yoda	Independent Outside Director	no data	no data	no data
Toshihiro Ishikiriyama	Independent Outside Director	8.8yrs	no data	0.0064% ¥ 6.4m
Yutaka Atomi	Independent Outside Director	1.8yrs	no data	no data
Takashi Suetsuna	Independent Outside Director	no data	no data	no data
Yuko Hayashi	Independent Outside Director	no data	no data	no data

4.3yrs

Average Tenure

64.5yo

Average Age

Experienced Board: 4552's board of directors are considered experienced (4.3 years average tenure).

JCR Pharmaceuticals Management

Management criteria checks 2/4

Key information

Recent management updates

JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes

Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Appoints Yoh Ito as Senior Corporate Officer

JCR Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Appoints Pascal Yoshida as Senior Director, Head of Medical Affairs Unit

JCR Pharmaceuticals Co., Ltd. Appoints Kazutoshi Mihara as Senior Director, Research Division and Director, CMC Development Research Institute

Recent updates

Upcoming dividend of JP¥10.00 per share

JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from FTSE All-World Index (USD)

JCR Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on May 10, 2024

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes

Now 22% overvalued

JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Price target decreased by 10% to JP¥1,657

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Jan 26, 2024

New major risk - Share price stability

JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

JCR Pharmaceuticals Co., Ltd. Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)

Upcoming dividend of JP¥10.00 per share at 1.5% yield

Investor sentiment improves as stock rises 18%

PHC IVD and JCR Announce GROWJECTOR® Duo

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2024 Results on Oct 25, 2023

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Consensus EPS estimates increase by 13%

First quarter 2024 earnings released: EPS: JP¥12.90 (vs JP¥11.05 in 1Q 2023)

Price target decreased by 7.4% to JP¥1,859

JCR Receives Approval to Start Global Phase I/II Clinical Trial for JR-441 for the Treatment of Mucopolysaccharidosis Type III A (MPS IIIA)

Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Receives an Approval for Expanded Indication of Growject®? in Short Stature Due to SHOX-Deficiency

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 20%

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Jul 26, 2023

Consensus EPS estimates fall by 24%

Full year 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued after recent price drop

Consensus revenue estimates fall by 17%

Upcoming dividend of JP¥10.00 per share at 1.3% yield

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

JCR Pharmaceuticals Co., Ltd. to Present Phase I/II Clinical Data on JR-171

Third quarter 2023 earnings released: EPS: JP¥20.89 (vs JP¥29.79 in 3Q 2022)

U.S. Fda Grants Rare Pediatric Disease Designation for JCR Pharmaceuticals Co., Ltd. Jr-141 for Mpsii

JCR Pharmaceuticals Co., Ltd. Appoints Yoh Ito as Senior Corporate Officer

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Announces Interim Dividend Payable on December 9, 2022; Provided Dividend Guidance for Fiscal 2023

Now 20% undervalued after recent price drop

JCR to Initiate Development of New Drug Candidate for Fucosidosis

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. Announces Interim Dividend on Retained Earnings, Payable on December 9, 2022

Price target decreased to JP¥2,861

Now 21% undervalued after recent price drop

Upcoming dividend of JP¥10.00 per share

Jcr Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

JCR Pharmaceuticals Co., Ltd. Announces Update on Application for Manufacturing and Marketing Approval of JR-141 for Treatment of MPS II (Hunter Syndrome) in Brazil

First quarter 2023 earnings released: EPS: JP¥11.05 (vs JP¥12.39 in 1Q 2022)

JCR Pharmaceuticals Co., Ltd Files for Expanded Use GROWJECT for Short Stature Due to SHOX-Deficiency

JCR Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Appoints Pascal Yoshida as Senior Director, Head of Medical Affairs Unit

JCR Pharmaceuticals Co., Ltd. Appoints Kazutoshi Mihara as Senior Director, Research Division and Director, CMC Development Research Institute

JCR Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Jan 26, 2023

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal Year 2022

JCR Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 22, 2022

Less than half of directors are independent

JCR Pharmaceuticals Co., Ltd. to Report Fiscal Year 2022 Results on May 12, 2022

Upcoming dividend of JP¥10.00 per share